Portfolio

OFA

Why oncology trials terminate and which sponsors show repeated discontinuation patterns.

Sponsor Intelligence Atlas

Which sponsors show recurring trial discontinuation, operational, portfolio, or evidence-risk patterns.

Access IQ

See where healthcare demand is rising before capacity, access pathways, and local systems catch up. Directional intelligence from public signals — not medical, financial, legal, reimbursement, or investment advice.

Trial Landscape Atlas

Map clinical-trial activity by sponsor, indication, mechanism, geography, phase, and status.

PharmaTech Atlas

Where evidence momentum is building across pharma and biotech technology classes.

Patent Cliff Monitor

Which assets face exclusivity loss across therapeutic areas and time horizons.

Pharma Exclusivity Atlas

Track patent, SPC, regulatory exclusivity, and loss-of-protection timelines across key European markets.

Evidence Twin

Build source-linked evidence packs around a product, mechanism, indication, company, or strategic question.

Mechanism Graveyard

Identify mechanisms, modalities, and therapeutic approaches with repeated historical discontinuation signals.

AccessWatch EU Platform

A roadmap platform concept for EU market-access and public policy intelligence. The live DIOS demo build is available separately as AccessWatch EU.

Trial Design Atlas

Compare endpoint, eligibility, comparator, enrollment, and study-design patterns across trial archetypes.

Custom Research Engine

Design a pharma intelligence workflow around your own strategic question, source mix, and output format.

Sponsors with Repeated Oncology Discontinuations

A public-data DIOS build using the OFA evidence backbone to structure sponsor-level oncology discontinuation context, approved source layers, and review-required research outputs.

Public-data only. Not predictive. Human review required.

BTK / CLL Competitive Landscape

A worked CI/BD showcase showing how Lippershey turns a mechanism-and-indication question into a competitive pipeline landscape with harmonized values, selected analytics, AI review, and provenance guardrails.

Illustrative scenario using synthetic example data. Not live sourced intelligence.

Oncology Patent Cliff Intelligence

Track oncology assets approaching patent or exclusivity cliffs using public regulatory, patent, clinical, literature, and provenance layers.

Public-data intelligence shell; evidence expansion requires controlled extract review.

Pipeline / Trial Landscape Intelligence

Map public clinical-trial and literature signals across sponsors, indications, phases, mechanisms, and evidence maturity.

Public-data intelligence shell; evidence expansion requires controlled extract review.

AccessWatch EU

A public-data DIOS build for EMA, HTA, trial, literature, missing-evidence and cross-source misalignment review across the EU access evidence context.

Public-data only. Not predictive. Human review required.